Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Enzyme:CYP3A4: Revision history

From Pharmacopedia

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 May 2026

20 May 2026

  • curprev 18:5518:55, 20 May 2026 MDElliottMD talk contribs 22,943 bytes +1,226 Revise CYP3A4 Phenotype categories section per parser-claude 2026-05-20: the earlier text flatly stated CYP3A4 has no metabolizer-phenotype classification. That is true for CPIC but not for DPWG, which tiers CYP3A4 into PM/IM/NM on the CYP3A4*22 allele. New text states the CPIC/DPWG disagreement, links the three Phenotype:CYP3A4 pages, and keeps the point that environmental induction/inhibition dominate CYP3A4 variability. Cites DPWG guideline PharmGKB PA166265421. See-also gains the three ph...

19 May 2026

  • curprev 22:3922:39, 19 May 2026 MDElliottMD talk contribs 21,717 bytes +10,606 Consolidate enzyme entity page to canonical Pharmacopedia: sandbox location per Mark 2026-05-19. Full retrofitted version: history-first spine, collapsible-sortable substrate table, comprehensive-tables pointer, all PMIDs NCBI-eutils-verified, zero em-dashes. For CYP2D6/CYP3A4/CYP2C19 this replaces the earlier pre-retrofit draft with the full version; for the other 8 enzymes this is the first save at the canonical location. Resolves a cross-session sandbox-location duplication: the User:MDEll...
  • curprev 16:3216:32, 19 May 2026 MDElliottMD talk contribs 11,111 bytes +11,111 Pharmacogenomics entity page: CYP3A4. Second of 10 canonical enzyme pages in Phase 1 (after CYP2D6 yesterday). Sandboxed under Pharmacopedia:Pharmacogenomics sandbox/ until interface-claude registers the Enzyme: namespace; will move to Enzyme:CYP3A4 thereafter. Covers tissue distribution (gut + liver), substrate spectrum (~50% of all medicines), inhibitor strength/kinetic-class taxonomy (grapefruit mechanism-based story), inducer pharmacology (rifampin PXR/CAR), CYP3A5*3 cross-reference, summ...